Objective:
The interview discusses developments in gene therapy for inherited retinal diseases since Luxturna’s 2017 FDA approval.
Approach:
- Context: Interview conducted at the 2026 SARyV Meeting in Ushuaia, Argentina.
- Discussion: Nagiel discussed the status of gene therapy trials following the 2017 FDA approval of Luxturna.
Key Findings:
- Nagiel described a period with few developments after Luxturna’s approval.
- He noted that many IRD gene therapy trials are now ongoing.
- He cited a potential approval for Beacon Therapeutics’ laru-zova for X-linked retinitis pigmentosa caused by RPGR mutations.
Interpretation:
Nagiel said the number of ongoing trials gives him more energy and movement to proceed, and he hopes more therapies will become available.
Limitations:
- The edited interview excerpt provides no trial data or efficacy results.
Conclusion:
Nagiel described ongoing gene therapy trials for inherited retinal diseases and a potential approval for Beacon Therapeutics’ laru-zova for RPGR-associated X-linked retinitis pigmentosa.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
